Suvren in brain-injured children
Forty hyperkinetic children with patterns of organic brain damage were treated with a new type of “mental drug”, Suvren. Dosage varied from 100 to 250 mg. daily for periods of 3 to 17 months. Twenty-three patients showed striking improvement in action and behavior. No significant toxic reactions or...
Gespeichert in:
| Veröffentlicht in: | The Journal of pediatrics 1958-03, Vol.52 (3), p.259-263 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 263 |
|---|---|
| container_issue | 3 |
| container_start_page | 259 |
| container_title | The Journal of pediatrics |
| container_volume | 52 |
| creator | Low, Niels L. Myers, Garth G. |
| description | Forty hyperkinetic children with patterns of organic brain damage were treated with a new type of “mental drug”, Suvren. Dosage varied from 100 to 250 mg. daily for periods of 3 to 17 months. Twenty-three patients showed striking improvement in action and behavior.
No significant toxic reactions or untoward side effects were demonstrated.
Our results indicate that Suvren isa safe and useful chemotherapeutic agent in the treatment of hyperactive children with brain damage. |
| doi_str_mv | 10.1016/S0022-3476(58)80111-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_82109048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347658801110</els_id><sourcerecordid>82109048</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-5b6a3aa252201f3bbb500d5d9c97711326b88f88d19e22a7fbd4225d540fd2493</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwCaCsECwCYzt2nBVCFS-pEovC2vJjIlylCdhNJf6e9CFYsprFnDujewg5p3BDgcrbOQBjOS9KeSXUtQJKaQ4HZEyhKnOpOD8k419kRE5SWgBAVQAckxHlgkko1Zhk834dsc1Cm9loQpuHdtFH9Jn7CI0fNqfkqDZNwrP9nJD3x4e36XM-e316md7PcsclX-XCSsONYYIxoDW31goAL3zlqrKklDNplaqV8rRCxkxZW18wJrwooPasqPiEXO7ufsbuq8e00suQHDaNabHrk1ZsaAaFGkCxA13sUopY688YliZ-awp6o0Zv1ehNby2U3qrRMOQu9g96u0T_l9q7GIC7HYBDzXXAqJML2Dr0IaJbad-Ff178AEmscMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>82109048</pqid></control><display><type>article</type><title>Suvren in brain-injured children</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Low, Niels L. ; Myers, Garth G.</creator><creatorcontrib>Low, Niels L. ; Myers, Garth G.</creatorcontrib><description>Forty hyperkinetic children with patterns of organic brain damage were treated with a new type of “mental drug”, Suvren. Dosage varied from 100 to 250 mg. daily for periods of 3 to 17 months. Twenty-three patients showed striking improvement in action and behavior.
No significant toxic reactions or untoward side effects were demonstrated.
Our results indicate that Suvren isa safe and useful chemotherapeutic agent in the treatment of hyperactive children with brain damage.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(58)80111-0</identifier><identifier>PMID: 13526078</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Brain ; Brain Injuries ; Child ; Hemorrhage - injuries ; Humans ; Hypnotics and Sedatives - therapeutic use ; Infant ; Movement Disorders ; Old Medline</subject><ispartof>The Journal of pediatrics, 1958-03, Vol.52 (3), p.259-263</ispartof><rights>1958 The C. V. Mosby Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-5b6a3aa252201f3bbb500d5d9c97711326b88f88d19e22a7fbd4225d540fd2493</citedby><cites>FETCH-LOGICAL-c363t-5b6a3aa252201f3bbb500d5d9c97711326b88f88d19e22a7fbd4225d540fd2493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0022-3476(58)80111-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/13526078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Low, Niels L.</creatorcontrib><creatorcontrib>Myers, Garth G.</creatorcontrib><title>Suvren in brain-injured children</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>Forty hyperkinetic children with patterns of organic brain damage were treated with a new type of “mental drug”, Suvren. Dosage varied from 100 to 250 mg. daily for periods of 3 to 17 months. Twenty-three patients showed striking improvement in action and behavior.
No significant toxic reactions or untoward side effects were demonstrated.
Our results indicate that Suvren isa safe and useful chemotherapeutic agent in the treatment of hyperactive children with brain damage.</description><subject>Brain</subject><subject>Brain Injuries</subject><subject>Child</subject><subject>Hemorrhage - injuries</subject><subject>Humans</subject><subject>Hypnotics and Sedatives - therapeutic use</subject><subject>Infant</subject><subject>Movement Disorders</subject><subject>Old Medline</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1958</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EoqXwCaCsECwCYzt2nBVCFS-pEovC2vJjIlylCdhNJf6e9CFYsprFnDujewg5p3BDgcrbOQBjOS9KeSXUtQJKaQ4HZEyhKnOpOD8k419kRE5SWgBAVQAckxHlgkko1Zhk834dsc1Cm9loQpuHdtFH9Jn7CI0fNqfkqDZNwrP9nJD3x4e36XM-e316md7PcsclX-XCSsONYYIxoDW31goAL3zlqrKklDNplaqV8rRCxkxZW18wJrwooPasqPiEXO7ufsbuq8e00suQHDaNabHrk1ZsaAaFGkCxA13sUopY688YliZ-awp6o0Zv1ehNby2U3qrRMOQu9g96u0T_l9q7GIC7HYBDzXXAqJML2Dr0IaJbad-Ff178AEmscMg</recordid><startdate>195803</startdate><enddate>195803</enddate><creator>Low, Niels L.</creator><creator>Myers, Garth G.</creator><general>Mosby, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>195803</creationdate><title>Suvren in brain-injured children</title><author>Low, Niels L. ; Myers, Garth G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-5b6a3aa252201f3bbb500d5d9c97711326b88f88d19e22a7fbd4225d540fd2493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1958</creationdate><topic>Brain</topic><topic>Brain Injuries</topic><topic>Child</topic><topic>Hemorrhage - injuries</topic><topic>Humans</topic><topic>Hypnotics and Sedatives - therapeutic use</topic><topic>Infant</topic><topic>Movement Disorders</topic><topic>Old Medline</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Low, Niels L.</creatorcontrib><creatorcontrib>Myers, Garth G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Low, Niels L.</au><au>Myers, Garth G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Suvren in brain-injured children</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1958-03</date><risdate>1958</risdate><volume>52</volume><issue>3</issue><spage>259</spage><epage>263</epage><pages>259-263</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><abstract>Forty hyperkinetic children with patterns of organic brain damage were treated with a new type of “mental drug”, Suvren. Dosage varied from 100 to 250 mg. daily for periods of 3 to 17 months. Twenty-three patients showed striking improvement in action and behavior.
No significant toxic reactions or untoward side effects were demonstrated.
Our results indicate that Suvren isa safe and useful chemotherapeutic agent in the treatment of hyperactive children with brain damage.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>13526078</pmid><doi>10.1016/S0022-3476(58)80111-0</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 1958-03, Vol.52 (3), p.259-263 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_82109048 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Brain Brain Injuries Child Hemorrhage - injuries Humans Hypnotics and Sedatives - therapeutic use Infant Movement Disorders Old Medline |
| title | Suvren in brain-injured children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A12%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Suvren%20in%20brain-injured%20children&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Low,%20Niels%20L.&rft.date=1958-03&rft.volume=52&rft.issue=3&rft.spage=259&rft.epage=263&rft.pages=259-263&rft.issn=0022-3476&rft.eissn=1097-6833&rft_id=info:doi/10.1016/S0022-3476(58)80111-0&rft_dat=%3Cproquest_cross%3E82109048%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=82109048&rft_id=info:pmid/13526078&rft_els_id=S0022347658801110&rfr_iscdi=true |